Abstract: The present invention relates to a combination of compounds for a use in therapy and especially to a therapeutic combination for use in the treatment of tumours and/or cancer. In particular, the invention relates to a therapeutic combination that comprises a NKCC1 protein inhibitor and a microtubule inhibitor, optionally together with one or more additional chemotherapeutic agents or radiotherapy. The combined administration includes at least one NKCC1 protein inhibitor and at least one microtubule inhibitor.

Abstract: The invention relates to a liquid oral formulation of bumetanide for the treatment of autism, more particularly for the improvement of the Autism Spectrum Disorder (ASD) core symptoms, tuberous sclerosis complex, fragile X syndrome, Rett syndrome, Down syndrome, cancer and particularly gliomas, spinal cord lesions, chronic pain, brain trauma, cerebrovascular infarcts, various types of epilepsies, and also acute lung injury such as pneumonias or Severe Acute Respiratory Disease due to Coronavirus-2 (SARS-CoV-2). Said formulation is especially designed for paediatric populations. The invention relates also to a posology for the administration of said liquid oral formulation.

Abstract: A composition for treating Fragile X syndrome in a subject in need thereof, wherein the composition includes an effective amount of a modulator of a chloride transporter.

Abstract: A composition for treating Neurodegenerative Diseases with Parkinsonian Syndromes in a subject in need thereof, wherein the composition includes an effective amount of a modulator of a chloride transporter.

Abstract: Modulators of intracellular chloride concentration for treating down syndrome The present invention relates to a modulator of a chloride transporter for use in the treatment of Down syndrome.

Abstract: The invention relates to a compound which inhibits the importation of chloride into neurons or a compound which improve the outflow of chloride from neurons for use in the treatment of autism in a baby or a fetus in need thereof.

Abstract: Modulators of intracellular chloride concentration for treating down syndrome The present invention relates to a modulator of a chloride transporter for use in the treatment of Down syndrome.

Abstract: A compound which inhibits the importation of chloride into neurons and a compound which improve the outflow of chloride from neurons for the use in treatment of autism, a pharmaceutical composition for use in the treatment of autism including such compound and a pharmaceutically acceptable carrier are described.

Abstract: A composition for treating Neurodegenerative Diseases with Parkinsonian Syndromes in a subject in need thereof, wherein the composition includes an effective amount of a modulator of a chloride transporter.

Abstract: A composition for treating Fragile X syndrome in a subject in need thereof, wherein the composition includes an effective amount of a modulator of a chloride transporter.

Abstract: The invention relates to a compound which inhibits the importation of chloride into neurons or a compound which improve the outflow of chloride from neurons for use in the treatment of autism in a baby or a fetus in need thereof.

Abstract: A compound which inhibits the importation of chloride into neurons and a compound which improve the outflow of chloride from neurons for the use in treatment of autism, a pharmaceutical composition for use in the treatment of autism including such compound and a pharmaceutically acceptable carrier are described.

Abstract: A method of treating or preventing non-apoptotic excitotoxic acute neural lesions in a patient including administering a therapeutically effective amount of a substance that modulates expression or the function of a protein involved in cell cycles, and a pharmaceutical preparation for treating or preventing non-apoptotic excitotoxic acute neural lesions including a therapeutically effective amount of a substance that modulates expression or the function of a protein involved in the cell cycle.